Welcome to our dedicated page for Stoke Therapeutics news (Ticker: STOK), a resource for investors and traders seeking the latest updates and insights on Stoke Therapeutics stock.
Stoke Therapeutics develops RNA medicines intended to restore protein expression, using its TANGO approach and antisense oligonucleotides for diseases caused by insufficient gene output. Its lead investigational medicine, zorevunersen, is in development for Dravet syndrome, with earlier work directed at rare genetic neurodevelopmental and other haploinsufficiency diseases.
Company news commonly covers zorevunersen clinical data, EMPEROR study updates, financial results, capital resources, collaboration activity, board and governance changes, equity inducement grants under Nasdaq rules, and healthcare conference presentations.
Stoke Therapeutics (Nasdaq: STOK) announced that CEO Ian F. Smith will present at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 3:00 p.m. ET. A live webcast and archived replay will be available in the Investors & News section of Stoke's website.
Stoke Therapeutics (Nasdaq: STOK) appointed Clare Kahn, Ph.D. to its Board of Directors on April 7, 2026. Dr. Kahn brings 30+ years of regulatory strategy and drug development experience in rare genetic diseases, including roles at X-VAX, Pfizer, and GlaxoSmithKline.
Her addition is positioned to support advancement of zorevunersen as the company progresses its Phase 3 study in Dravet syndrome.
Stoke Therapeutics (Nasdaq: STOK) granted inducement stock options effective March 16, 2026, as material inducements under Nasdaq Listing Rule 5635(c)(4). The company granted options to purchase an aggregate of 58,650 shares to six new employees at an exercise price of $33.96 per share.
Each option vests over four years (25% after one year, then monthly over 36 months), has a 10-year term, and is subject to the 2023 Inducement Plan and related stock option agreements.
Stoke Therapeutics (BIIB) announced that CEO Ian F. Smith will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 2:30 p.m. ET. A live audio webcast and archived replay will be available in the Investors & News section of Stoke’s website.
The company is focused on RNA medicine and is developing zorevunersen as a potential first-in-class disease-modifying treatment for Dravet syndrome.
Stoke Therapeutics (Nasdaq: STOK) granted inducement stock options effective February 17, 2026, to five new employees totaling 22,950 shares under Nasdaq Listing Rule 5635(c)(4).
The options carry an exercise price of $31.09 (closing price on February 17, 2026), vest over four years with standard 1/4 one-year cliff and monthly vesting thereafter, and have a 10-year term under the 2023 Inducement Plan and related agreements.
Stoke Therapeutics (Nasdaq: STOK) announced the first patient has been dosed in the Phase 1 OSPREY study of STK-002, an investigational antisense medicine for Autosomal Dominant Optic Atrophy (ADOA).
The dose-escalating, open-label study will enroll ages 6–55, assess safety, tolerability and blood exposure as primary endpoints, and evaluate visual function, ocular structure and quality of life as secondary objectives. Dose escalation for the first four cohorts continues through 2026 and early 2027. Approximately 80% of people with ADOA are symptomatic by age 10 and about 50% may become legally blind; no approved treatments currently exist.
Stoke Therapeutics (Nasdaq: STOK) announced that CEO Ian F. Smith will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 2:30 p.m. ET.
A live audio webcast and archived replay will be available in the Investors & News section of Stoke's investor website.
Stoke Therapeutics (NASDAQ: STOK) signed a long-term lease for a 98,500 square-foot headquarters at 245 Fifth Avenue in Waltham, MA, with occupancy planned after its Bedford lease ends in late 2026. The site is lab-ready and certified LEED Gold and WiredScore Platinum, and Anchor Line Partners and Northwood Investors secured the transaction. Stoke discovered its lead investigational medicine, zorevunersen (developed with Biogen), in Bedford and has advanced it into late-stage development for Dravet syndrome. Management says the move aims to support commercialization preparation and expanded research using Stoke’s RNA platform. Cushman & Wakefield represented Stoke in the lease.
The lease was noted as one of the largest Greater Boston life sciences transactions in the past year and emphasizes Waltham’s connectivity to Route 128/I-95, I-90 and Route 2.
Stoke Therapeutics (Nasdaq: STOK) granted inducement stock options effective January 15, 2026, to nine new employees covering an aggregate of 74,020 shares of common stock under Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $29.28 per share (closing price on January 15, 2026), a 10-year term, and vest over four years: 25% at the one-year anniversary and the remainder monthly over 36 months, subject to continued employment and the 2023 Inducement Plan and option agreement terms.
Stoke Therapeutics (Nasdaq: STOK) and collaborator Biogen (Nasdaq: BIIB) updated timelines for zorevunersen in Dravet syndrome. Completion of enrollment of 150 patients in the Phase 3 EMPEROR study is now expected in Q2 2026, with a topline data readout planned for mid-2027 and a rolling NDA initiation targeted in the first half of 2027. A recent multidisciplinary FDA meeting raised requests for additional information; discussions are ongoing and no immediate program changes were agreed. As of Jan 9, 2026, ~60 patients are in screening, ~60 randomized/dosed, and the company held $391.7M in cash and equivalents, expected to fund operations into 2028.